Goldline Pharmaceutical Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹12(27.91%)
Premium (ELP)
Following its successful public offering, Goldline Pharmaceutical Limited's made its market debut on May 19, 2026 and is now actively traded on the BSEplatform. The IPO mobilized 27,00,000 Shares in total capital, including 27,00,000 Shares in primary equity infusion.
The offering was structured with a price band of ₹41 to ₹43 and minimum investment lots of 3000 shares. Investor participation during the subscription window from May 12, 2026 to May 14, 2026 demonstrated market confidence in the company's prospects.
The allotment process concluded on May 15, 2026, allocating shares to successful bidders. The listing represents the culmination of the IPO process, transitioning the company to publicly traded status with enhanced transparency and governance standards.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Goldline Pharmaceuticals markets pharmaceutical products under the “Goldline” brand, offering a wide range of medicines across five divisions—Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. These products cater to various medical specialties including physicians, cardiologists, pediatricians, orthopedics, neurologists, critical care experts, and cancer supportive care. Instead of manufacturing medicines directly, the company works with third-party manufacturers who produce products based on its research and specifications while ensuring quality and regulatory compliance. Goldline sells its products through a network of distributors, retailers, and wholesalers, and also supports hospitals and healthcare providers with procurement and supply services. The company currently partners with 15 manufacturers and 7 distributors, with operations spread across states like Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Asset-Light & Scalable Business Model : Outsourced manufacturing approach reduces capital requirements and supports expansion.
- Diversified Pharmaceutical Portfolio : Wide range of products across multiple therapeutic segments reduces dependency on one category.
- Strong Distribution & Supplier Network : Established relationships with manufacturers and distributors ensure smooth operations.
- Dependence on Third-Party Manufacturers : Reliance on external manufacturers may impact quality control and supply continuity.
- Regulatory Compliance Risks : Pharmaceutical industry is highly regulated and subject to strict approvals and standards.
- Limited Geographic Presence : Operations concentrated in selected Indian states may restrict nationwide growth.
- Amol Laxmikant Mujumdar
- Swapan Premprakash Khandelwal
Goldline Pharmaceutical Limited
Bigshare Services Private Limited